AI and Healthcare How AI Screening Is Shaping the Future of Drug Discovery with Tom Neyarapally and Mika Newton
Feb 3, 2025
Tom Neyarapally, Founder and CEO at Archetype Therapeutics, and Mika Newton, a notable figure in healthcare innovation, dive into the revolutionary impact of AI on drug discovery. They discuss how machine learning and real-world data are reshaping treatments and reducing costs. The pair emphasizes the importance of collaboration between AI technology and clinical expertise to speed up therapy development. They also tackle challenges such as data access and the need for personalized medication, showcasing a new era of patient-centered approaches.
AI Snips
Chapters
Transcript
Episode notes
Key Enablers of AI Drug Discovery
- AI-enabled drug discovery advanced by combining proper data, evolving ML tools, and modern compute power.
- Integration of patient clinical and molecular profiling is critical and has recently become feasible.
Leveraging Massive Compute Early On
- Early innovations involved harnessing thousands of processors to build ensembles of cancer models.
- This allowed simultaneous evaluation of many hypotheses, greatly advancing model accuracy and scale.
Patient-Centric Drug Discovery Shift
- Drug discovery often suffers from disconnected steps that separate biology, screening, and clinical testing.
- Starting drug discovery from patient data and disease biology can accelerate and improve success rates.